Dupont, B., Mariotte, D., Dugué, A. E., Clarisse, B., Grellard, J., Babin, E., Chauffert, B., Dakpé, S., Moldovan, C., Bouhier‐Leporrier, K., Reimund, J., Di Fiore, F., Zanetta, S., Mailliez, A., Do, P., Peytier, A., Galais, M., Florescu, C., Schott, R., Le Mauff, B., & Gervais, R. (n.d.). utility of serum anti‐cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab. British journal of clinical pharmacology, 83, 623–631. http://access.bl.uk/ark:/81055/vdc_100041767483.0x00002b